Data compiled by Redley Lamar · ChainSifter Intelligence
6Suppliers
0Customers
1Debt Items
7Related Chains
Source-Backed Evidence Depth
MiNK Therapeutics, Inc. (INKT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
8Total relationships
4Distinct source URLs
7High confidence
0.878Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
MiNK Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
AGENUS
AGENUS
90%
Agenus has also agreed to provide the Company with Agenus' biological material upon written request in order for the Company to use such material in its development activities of a combination therapy.
AGENUS-INC
AGENUS-INC
90%
Mr. Charette, provides services to the Company through an Amended and Restated Intercompany Services Agreement between the Company and Agenus.
AUTONOMOUS-THERAPEUTICS
AUTONOMOUS-THERAPEUTICS
90%
Advance research collaboration with Autonomous Therapeutics(October 2024) to evaluate encrypted RNA™ technologies in combination with MiNK-215 and agenT-797 in metastatic solid tumor models;
C-FURTHER
C-FURTHER
90%
Leverage a collaboration with C-Further to support an optimal TCR-PRAME candidate for pediatric patients with cancer.
IMMUNOSCAPE
IMMUNOSCAPE
90%
A collaboration with Immunoscape (December 2023) to discover and develop TCR-based therapies across multiple immune cell modalities;
Reciprocal relationship from AGEN graph: ser Upsize Option liability and equity-classified Ligand Warrants were recognized based on their fair values and the residual was allocated to a liability rel…
MiNK Therapeutics, Inc. Customers
No clients on recordMiNK Therapeutics, Inc. does not appear to disclose named customer relationships in its verified regulatory filings. Many companies do not publicly name customers in regulatory disclosures.
MiNK Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
INKT-DEBT-10286
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
MiNK Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for MiNK Therapeutics, Inc..
MiNK Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
INKT-OWNER-HORIZON-FINANCIAL-SERVICES-LLC
HORIZON FINANCIAL SERVICES, LLC
90%
13F overlay lists HORIZON FINANCIAL SERVICES, LLC as top holder; 1 tracked holders.
MiNK Therapeutics, Inc. Extended Supply Chain Network
